Inhibitory effects of curcumenol on human liver cytochrome P450 enzymes

Phytotherapy Research

Volumn 24, Issue 8, 2010, Pages 1213-1216

  Sun, Dong Xue ^a   Fang, Zhong Ze ^b,c   Zhang, Yan Yan ^b,c   Cao, Yun Feng ^a   Yang, Ling ^b   Yin, Jun ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

^c UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

Curcumenol; Cytochrome P450 (CYP); Drug drug interaction; Enzyme kinetics; Human liver microsomes; Inhibition

Indexed keywords

CURCUMENOL; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; LIVER ENZYME; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TURMERIC; UNCLASSIFIED DRUG; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A INHIBITOR; ENZYME INHIBITOR; SESQUITERPENE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DOG; DRUG BLOOD LEVEL; ENZYME INHIBITION; HUMAN; IC 50; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; SINGLE DRUG DOSE; ANIMAL; CHEMISTRY; CURCUMA; DRUG EFFECTS; DRUG INTERACTION; ENZYMOLOGY; FEMALE; IC50; LIVER; LIVER MICROSOME; MALE;

CANIS FAMILIARIS; CURCUMA LONGA; CURCUMA ZEDOARIA;

ANIMALS; AREA UNDER CURVE; CURCUMA; CYTOCHROME P-450 CYP3A INHIBITORS; DOGS; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; LIVER; MALE; MICROSOMES, LIVER; SESQUITERPENES;

EID: 77955646498     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.3102     Document Type: Article

References (20)

1. Bailey DG, Malcolm J, Arnold O, Spence JD. 1998. Grapefruit juice-drug interactions. Br J Clin Pharmacol 46(2): 101-110.
2. Beijnen JH, Schellens JHM. 2004. Drug interactions in oncology. Lancet Oncol 5(8): 489-496.
3. Fujita T, Matsumoto Y, Ozaki M, Majima M, Kumagai Y, Ohtani Y. 2006. Comparison of maximum drug concentration and area under the time-concentration curve between humans and animals for oral and intravenous Investigational drugs. J Clin Pharmacol 46(6): 674-692. (Pubitemid 43920232)
4. Goldman P. 2001. Herbal medicines today and the roots of modern pharmacology. Ann Intern Med 135(8): 594-600. (Pubitemid 33010195)
5. Iwata H, Tezuka Y, Kadota S, Hiratsuka A, Watabe T. 2004. Identification and characterization of potent CYP3A4 inhibitors in Schisandra fruit extract. Drug Metab Dispos 32(12): 1351-1358. (Pubitemid 39564554)
6. Johne A, Brockmoller J, Bauer S, Maurer A, Langheinrich M, Roots I. 1999. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther 66(4): 338-345. (Pubitemid 29494126)
7. Liu Y, Zhang JW, Li W, Ma H, Sun J, Deng MC, Yang L. 2006. Ginsenoside metabolites, rather than naturally occurring ginsenosides, lead to inhibition of human cytochrome P450 enzymes. Toxicol Sci 91(2): 356-364. (Pubitemid 43827288)
8. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. 1951. Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275.
9. Obach RS, Walsky RL, Venkatakrishnan K. 2007. Mechanism- based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 35(2): 246-255. (Pubitemid 46148737)
10. Omura T, Sato R. 1964. The carbon monoxide-binding pigment of liver microsomes. I. exidence for its hemoprotein nature. J Biol Chem 239: 2370-2385.
11. Pharmacopoeia Commission of PRC. 2000. Pharmacopoeia of the People's Republic of China (1st edn). Chemical Industry Press: Beijing.
12. Purnapatre K, Khattar SK, Saini KS. 2008. Cytochrome P450s in the development of target-based anticancer drugs. Cancer Lett 259(1): 1-15. (Pubitemid 350253101)
13. Siepmann M, Kirch W. 2000. Drug-drug interactions of new active substances: mibefradil example. Eur J Clin Pharmacol 56(3): 273-273. (Pubitemid 30456690)
14. Wang YH, Jones DR, Hall SD. 2004. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos 32(2): 259-266.
15. Yang FQ, Wang YT, Li SP. 2006. Simultaneous determination of 11 characteristic components in three species of Curcuma rhizomes using pressurized liquid extraction and high-performance liquid chromatography. J Chromatogr A 1134: 226-231.
16. Zhang H, Kang N, Qiu F, Qu GX, Yao XS. 2007a. Four novel metabolites from microbial transformation of curcumol by Cunninghamella blakesleana. Chem Pharm Bull 55(3): 451-454. (Pubitemid 46513412)
17. Zhang JW, Liu Y, Li W, Hao DC, Yang L. 2006. Inhibitory effect of medroxyprogesterone acetate on human liver cytochrome P450 enzymes. Eur J Clin Pharmacol 62(7): 497-502.
18. Zhang R, Wang BJ, Zhao HL, Li XL, Wei CM, Guo RC. 2007b. Determination of curcumenol in plasma by HPLC-MS/MS method and its pharmacokinetics in Beagle dogs. Acta Pharmacol Sin 42(9): 973-977.
19. Zhang YY, Yang L. 2009. Interactions between human cytochrome P450 enzymes and steroids: physiological and pharmacological implications. Expert Opin Drug Metab Toxicol 5(6): 621-629.
20. Zhang YY, Liu Y, Zhang JW, Ge GB, Wang LM, Sun J, Yang L. 2009. Characterization of human cytochrome P450 isoforms involved in the metabolism of 7-epi-paclitaxel. Xenobiotica 39(4): 283-292.